

Andrew D Mumford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5040157/publications.pdf>

Version: 2024-02-01

56
papers

3,627
citations

279701

23
h-index

175177

52
g-index

66
all docs

66
docs citations

66
times ranked

6708
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
2	Guidelines for the use of platelet transfusions. British Journal of Haematology, 2017, 176, 365-394.	1.2	354
3	Whole-genome sequencing of patients with rare diseases in a national health system. Nature, 2020, 583, 96-102.	13.7	338
4	Guideline for the diagnosis and management of the rare coagulation disorders. British Journal of Haematology, 2014, 167, 304-326.	1.2	266
5	Transcriptional diversity during lineage commitment of human blood progenitors. Science, 2014, 345, 1251033.	6.0	253
6	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	0.6	157
7	Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood, 2019, 134, 2082-2091.	0.6	131
8	A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood, 2016, 127, 2903-2914.	0.6	121
9	Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. Genome Medicine, 2015, 7, 36.	3.6	119
10	Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica, 2016, 101, 1170-1179.	1.7	119
11	Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel. Blood, 2012, 120, 5041-5049.	0.6	92
12	A dominant gain-of-function mutation in universal tyrosine kinase <i>SRC</i> causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies. Science Translational Medicine, 2016, 8, 328ra30.	5.8	87
13	Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood, 2016, 128, 2717-2728.	0.6	72
14	Identification and characterization of a novel P2Y12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood, 2009, 113, 4110-4113.	0.6	67
15	Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia. Journal of Clinical Investigation, 2017, 127, 814-829.	3.9	57
16	A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood, 2010, 115, 363-369.	0.6	56
17	VPS33B regulates protein sorting into and maturation of α -granule progenitor organelles in mouse megakaryocytes. Blood, 2015, 126, 133-143.	0.6	56
18	An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets. Blood, 2011, 118, 5641-5651.	0.6	44

#	ARTICLE	IF	CITATIONS
19	Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia. <i>Blood</i> , 2017, 129, 520-524.	0.6	42
20	Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. <i>Thrombosis Research</i> , 2021, 201, 100-112.	0.8	42
21	Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder. <i>Blood Advances</i> , 2018, 2, 2341-2346.	2.5	33
22	<i>TUBB1</i> variants and human platelet traits. <i>Platelets</i> , 2018, 29, 209-211.	1.1	31
23	A multicentre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and health-care resource use following cardiac surgery (TITRe2). <i>Health Technology Assessment</i> , 2016, 20, 1-260.	1.3	26
24	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. <i>BMJ Open</i> , 2018, 8, e024427.	0.8	20
25	Understanding the therapeutic action of recombinant factor VIIa in platelet disorders. <i>Platelets</i> , 2008, 19, 571-581.	1.1	19
26	A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction. <i>Thrombosis and Haemostasis</i> , 2014, 112, 923-932.	1.8	19
27	Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 952-960.	1.1	18
28	ACTN1 variants associated with thrombocytopenia. <i>Platelets</i> , 2017, 28, 625-627.	1.1	18
29	Manufacturing variables and hemostatic function of cold-stored platelets: a systematic review of the literature. <i>Transfusion</i> , 2019, 59, 2722-2732.	0.8	16
30	A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2209-2214.	1.9	16
31	Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors. <i>Thrombosis and Haemostasis</i> , 2015, 113, 826-837.	1.8	15
32	Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet) Trial. <i>Circulation</i> , 2021, 144, 140-150.	1.4	10
33	<i>TBXA2R</i> gene variants associated with bleeding. <i>Platelets</i> , 2018, 29, 739-742.	1.1	12
34	Tissue Factor in the Myocardium: Evidence of Roles in Haemostasis and Inflammation. <i>Disease Markers</i> , 2004, 20, 353-358.	0.6	10
35	Monoallelic loss-of-function THPO variants cause heritable thrombocytopenia. <i>Blood Advances</i> , 2020, 4, 920-924.	2.5	10
36	Epigenetic Regulation of <i>F2RL3</i> Associates With Myocardial Infarction and Platelet Function. <i>Circulation Research</i> , 2022, 130, 384-400.	2.0	10

#	ARTICLE	IF	CITATIONS
37	Advances in understanding the pathogenesis of hereditary macrothrombocytopenia. <i>British Journal of Haematology</i> , 2021, 195, 25-45.	1.2	9
38	Higher body mass index raises immature platelet count: potential contribution to obesity-related thrombosis. <i>Platelets</i> , 2022, 33, 869-878.	1.1	9
39	Detection of coagulopathy in paediatric heart surgery [DECISION study]: study protocol. <i>BMC Hematology</i> , 2015, 15, 11.	2.6	8
40	Diagnosis and management of severe congenital protein C deficiency (SCPCD): Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1735-1743.	1.9	8
41	Diagnostic and therapeutic medical devices for safer blood management in cardiac surgery: systematic reviews, observational studies and randomised controlled trials. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-406.	0.4	7
42	Near-patient coagulation testing to predict bleeding after cardiac surgery: a cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 242-251.	1.0	6
43	Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating "target trials" (the ADAPTT Study). <i>BMJ Open</i> , 2019, 9, e029388.	0.8	6
44	<i>FLNA</i> variants associated with disorders of platelet number or function. <i>Platelets</i> , 2020, 31, 1097-1100.	1.1	6
45	Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2127-2135.	1.9	6
46	Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 529.	0.7	5
47	Prediction of Bleeding in Pediatric Cardiac Surgery Using Clinical Characteristics and Prospective Coagulation Test Results. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2021, , .	0.4	5
48	Genetic Techniques Used in the Diagnosis of Inherited Platelet Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 685-694.	1.5	4
49	TEG PlateletMapping assay results may be misleading in the presence of cold stored platelets. <i>Transfusion</i> , 2020, 60, S119-S123.	0.8	3
50	The EHA Research Roadmap: Platelet Disorders. <i>HemaSphere</i> , 2021, 5, e601.	1.2	3
51	Functional Variations In Genes Encoding Platelet G-Protein Coupled Receptors In Unselected and Platelet Function Disorder Populations. <i>Blood</i> , 2013, 122, 3511-3511.	0.6	3
52	Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 126-133.	0.7	2
53	Low multiple electrode aggregometry platelet responses are not associated with non-synonymous variants in G-protein coupled receptor genes. <i>Thrombosis Research</i> , 2015, 136, 818-824.	0.8	0
54	Inherited Bleeding Disorders in Pregnancy: Platelet Defects. , 2012, , 143-156.		0

#	ARTICLE	IF	CITATIONS
55	Inherited Bleeding Disorders in Pregnancy: Platelet Defects. , 2015, , 223-236.		0
56	Abstract 17197: The Value of Routine Near-patient Haemostasis Testing for Predicting Bleeding After Cardiac Surgery. Circulation, 2015, 132, .	1.6	0